- Products and Services
- Science & Technology
- Blog and Events
Blood-based mutation analysis requires a sensitive technology. Sysmex Inostics' OncoBEAM technology is based on an enhanced digital PCR called BEAMing which combines emulsion PCR with magnetic beads and flow cytometry for the highly sensitive detection and quantification of mutant tumor DNA molecules. Our BEAMing technology delivers increased sensitivity compared to other liquid biopsy methods providing reliable molecular information for timely and non-invasive treatment selection and enhanced prediction of resistance to therapy.
The video below illustrates the principal steps of the BEAMing process: PCR amplification, formation of water-in-oil emulsions, breaking of the emulsions and hybridization to fluorescent probes, and flow cytometry readout.
Detect important mutations from 0.02% to 0.04% allele frequency using BEAMing enhanced digital PCR technology. Learn more about the single gene and gene panel testing available here.
Interested in seeing how BEAMing could be used for clinical testing? Access the resource “Sysmex OncoBEAM circulating tumor DNA testing in clinical practice” here (PDF)